Product Name: Akt2-1
Product Number: AB-NK130-4
| Size: | 25 µg | Price: | 89.00 | |
| $US |
Target Full Name: RAC-beta serine/threonine-protein kinase
Target Alias: Akt2; PKB beta; RAC-beta serine,threonine protein kinase; RAC-PK-beta; PKBB; PRKBB; HIHGHH; PKBBETA; RAC-BETA; CCDS12552.1; ENSG00000105221
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK130-4
Antibody Target Type: Pan-specific
Protein UniProt: P31751
Protein SigNET: P31751
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human Akt2 (PKBb) sequence peptide Cat. No.: PE-01AWP99
Target Alias: Akt2; PKB beta; RAC-beta serine,threonine protein kinase; RAC-PK-beta; PKBB; PRKBB; HIHGHH; PKBBETA; RAC-BETA; CCDS12552.1; ENSG00000105221
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK130-4
Antibody Target Type: Pan-specific
Protein UniProt: P31751
Protein SigNET: P31751
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human Akt2 (PKBb) sequence peptide Cat. No.: PE-01AWP99
Antibody Immunogen Sequence: CEMEVAVSKARAKVTM
Antibody Immunogen Description: Corresponds to amino acid residues E135 to M149; Pre-kinase catalytic domain
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Immunogen Description: Corresponds to amino acid residues E135 to M149; Pre-kinase catalytic domain
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.75 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 1 µg/ml for immunoblotting
Antibody Potency: Strong immunoreactivity with recombinant human Akt2 on protein dot blots.
Antibody Species Reactivity: Human
Antibody Concentration: 0.75 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 1 µg/ml for immunoblotting
Antibody Potency: Strong immunoreactivity with recombinant human Akt2 on protein dot blots.
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 55-60 kDa.
Antibody Specificity: High
Antibody Cross Reactivity: No immunoreactivity on protein dot blots with recombinant human Akt1 and Akt3.
Related Product 1: Akt2-1 blocking peptide
Related Product 2: Akt2 pan-specific antibody (Cat. No.: AB-NK130-9P)
Related Product 3: Akt2 (PKB beta) pan-specific antibody (Cat. No.: AB-NK130-3)
Related Product 4: Akt2-2 pan-specific antibody (Cat. No.: AB-NK130-8)
Related Product 5: Akt2-3 pan-specific antibody (Cat. No.: AB-NK130-9)
Antibody Specificity: High
Antibody Cross Reactivity: No immunoreactivity on protein dot blots with recombinant human Akt1 and Akt3.
Related Product 1: Akt2-1 blocking peptide
Related Product 2: Akt2 pan-specific antibody (Cat. No.: AB-NK130-9P)
Related Product 3: Akt2 (PKB beta) pan-specific antibody (Cat. No.: AB-NK130-3)
Related Product 4: Akt2-2 pan-specific antibody (Cat. No.: AB-NK130-8)
Related Product 5: Akt2-3 pan-specific antibody (Cat. No.: AB-NK130-9)
Related Product 6: PKB2-PCT (Akt2-4) pan-specific antibody (Cat. No.: AB-NK130-5)
Related Product 7: AktSubtide - Akt1 (PKBa) protein kinase substrate peptide
Related Product 8: GSK3b (3-12) KinSub - Glycogen synthase kinase 3-beta (GSK3b) N-terminus (G3-E12, human) peptide; Akt protein kinase substrate peptide
Related Product 7: AktSubtide - Akt1 (PKBa) protein kinase substrate peptide
Related Product 8: GSK3b (3-12) KinSub - Glycogen synthase kinase 3-beta (GSK3b) N-terminus (G3-E12, human) peptide; Akt protein kinase substrate peptide
Scientific Background: Akt2 (PKBB, PRKBB) is a protein-serine/threonine kinase of the AGC group and Akt family. Its cell signalling activities involve activating cell surival and proliferation, increasing metabolism, and angiogenesis. Its interaction network contains over 100 substrates which includes inhibiting p53 via downstream signalling, activating mTOR, inhibition of GSK3b, and inhibition of cyclins .Phosphorylation of T309 and S474 increases phosphotransferase activity. Cancer-related mutations in human tumours point to a gain of function of the protein kinase. Insertional mutagenesis studies in mice also support a role for this protein kinase in mouse cancer oncogenesis. The active form of the protein kinase normally acts to promote tumour cell proliferation. In many cancers, Akt2 is found to be overexpressed and amplified. It is also linked with invasion, cell migration and induction of angiogenesis. It is important in cell survival regulation, insulin signalling, angiogenesis and tumour formation. Defects in Akt2 contributes to suspectibility to breast cancer and the malignancy of a subset of human ductal pancreatic cancer. Akt2 promotes metastasis of tumour cells, but does not affect the latency of tumour development. Together with Akt3, it has a critical role in glioblastomas. However, there are no prominent mutations in Akt2 in human cancers, with a relatively dispersed pattern of low level mutations through out the full length of the protein. In cancer, it is found to be overexpressed and amplified. It is also linked with invasion, cell migration and induction of angiogenesis.
Figure 1. Dot blotting Akt2-1 antibody with recombinant purified proteins.
© Kinexus Bioinformatics Corporation 2017